Replies to post #343399 on NorthWest Biotherapeutics Inc (NWBO)

[flipper44]

Yes, but most people probably did not panic because they realized the reasons for September to January price rise was primarily closing in on DCVax-l TLD, and more recently, BMY showing that CI mono-therapy post resection doesn’t work. The latter ended a string of immunotherapeutic trial failures that otherwise might have provided near term competition to DCVax-l, should it prove successful.